Dordaviprone
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 33 publications
H3K27M-mutant diffuse midline glioma pharmacotherapy: Clinical evidence and practice implications of dordaviprone.
Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
Published: June 19, 2026
Diffuse Midline Gliomas: Clinical, Diagnostic, and Therapeutic Perspectives.
Journal: Biomedicines
Published: February 05, 2026
The role of dordaviprone in the multidisciplinary management of diffuse midline glioma.
Journal: Surgical neurology international
Published: December 25, 2025
Emerging Targeted Therapies and Ongoing Clinical Trials in Pediatric Brain Tumors
Journal: No shinkei geka. Neurological surgery
Published: December 09, 2025
ONC206 demonstrates potent anti-tumorigenic activity and is a potential novel therapeutic strategy for high-risk medulloblastoma.
Journal: bioRxiv : the preprint server for biology
Published: November 19, 2025
Dordaviprone for Diffuse Midline Glioma: A Landmark Approval or a Premature Step?
Journal: Neuro-oncology
Published: November 13, 2025
Dordaviprone in H3K27M-mutant diffuse midline glioma: an editorial on emerging targeted therapy.
Journal: Annals of medicine and surgery (2012)
Published: September 27, 2025
Dordaviprone (Modeyso) for diffuse midline glioma.
Journal: The Medical letter on drugs and therapeutics
Published: September 22, 2025
ONC206 demonstrates potent anti-tumorigenic activity and is a potential novel therapeutic strategy for high-risk medulloblastoma.
Journal: Neuro-oncology
Published: September 18, 2025
Molecular mechanisms of mitochondrial AAA+ proteases.
Journal: The Journal of biological chemistry
Published: September 18, 2025
Last Updated: 06/30/2026